GlassScriptPhysician profile
Mary A Harrison
NPI 1003244021
$3,001.60
in general payments reported to CMS, 2019-2025
27 companies · $981 in 2025
The $981 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $271 · 2023: $452 · 2024: $1,148 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533 · Education: $47.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.31 |
| Education | $47.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.80 | 2024-2025 | Fasenra, Tezspire |
| Verona Pharma, INC. | $277.86 | 2025 | Ohtuvayre |
| Genzyme Corporation | $212.65 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $208.31 | 2021-2023 | Isentress, Delstrigo, Pifeltro |
| Mylan Specialty L.P. | $156.68 | 2023-2024 | Yupelri |
| Theratechnologies INC. | $153.16 | 2021-2023 | Egrifta, Trogarzo |
| Harmony Biosciences LLC | $151.61 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.94 | 2024-2025 | Dupixent |
| Axsome Therapeutics, INC. | $142.13 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $135.02 | 2023-2025 | Cuvitru |
| Grifols USA, LLC | $119.61 | 2024-2025 | Prolastin-C Liquid, Xembify |
| United Therapeutics Corporation | $116.85 | 2023-2025 | Remodulin, Remodulin, Orenitram |
| Jazz Pharmaceuticals INC. | $87.96 | 2024-2025 | |
| Pulmonx Corporation | $84.00 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $77.58 | 2024-2025 | Trelegy Ellipta, Arexvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $70.41 | 2022-2023 | Serostim |
| Tolmar, INC. | $62.89 | 2023 | |
| Janssen Biotech, INC. | $61.74 | 2022-2023 | Symtuza |
| Mannkind Corporation | $59.40 | 2022 | |
| Insmed, INC. | $52.45 | 2024-2025 | Arikayce |
| Viatris Specialty LLC | $42.44 | 2025 | Yupelri |
| Amgen INC. | $36.57 | 2024-2025 | Tezspire |
| Viiv Healthcare Company | $28.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2024 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.47 | 2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.35 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.